Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: NeuroInvestment who wrote (961)	6/27/2002 1:28:49 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 1834

Harry, I apologize if I am going on your nerve. I understand that I am asking for information which bios do not disclose to public very often, competitive reasons. By layman analogy (sonata versus 34060 versus ambien) I can not accept that simple omega-1 binding property (in addition to metabolite route and t1/2) are the only reasons which differentiate this compounds. My main effort is to speculate on prediction of the 34060 beyond few weeks efficacy. If you wish to comment on following? Does following: 25 min for TSO and 6 hr of TST (from ~7.0-7.5 hr total bad time) for placebo, and delta TST of 30 min for 34060, for real represent elderly chronic insomnia population? Miljenko